Furthermore, exploring the potential therapeutic strategy of combining a G6PD inhibitor with agents that induce oxidative stress holds promise for treating this specific subtype of KRAS-mutant NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.